Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer, which is resistant to the conventional chemotherapy and radiotherapy with a poor prognosis. Limited case reports have showed good response to the immunotherapy in PSC patients with high PD-L1 expression generally....
Main Authors: | Caibao Jin, Bin Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-06-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/507568 |
Similar Items
-
Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
by: Yanyang Liu, et al.
Published: (2021-10-01) -
Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
by: Jing Li, et al.
Published: (2021-05-01) -
Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
by: Takahiro Ota, et al.
Published: (2019-11-01) -
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis
by: Massimiliano Salati, et al.
Published: (2018-09-01) -
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01)